- Home
- LILA vs DMRA Comparison
LILA vs DMRA Comparison
Compare LILA & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILA | DMRA |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LILA | DMRA |
|---|---|---|
| Price | $8.69 | $122.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $13.00 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 577.1K | 336.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.55 | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,442,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.77 | $16.50 |
| 52 Week High | $9.04 | $34.89 |
Technical Indicators
Market Signals| Indicator | LILA | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 52.61 |
| Support Level | $7.10 | $28.16 |
| Resistance Level | $8.83 | $31.77 |
| Average True Range (ATR) | 0.28 | 1.47 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 56.36 | 32.66 |
Price Performance
Historical ComparisonAbout LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.